Boehringer Ingelheim Dealt New Blow In Nearly Two Years Of Review For Pradaxa In Australia
This article was originally published in PharmAsia News
Executive Summary
Australia’s Health Ministry calls for additional study of anticoagulant Pradaxa, dealing a fresh blow to Boehringer Ingelheim’s hopes of getting listed on the national reimbursement program nearly two years after initial regulatory approval.
You may also be interested in...
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.
Boehringer Ingelheim's Open Letter For Pradaxa Brings Australian PBS Back Into Spotlight
Pharmaceutical giant Boehringer Ingelheim took on the Australian federal government Nov. 2, calling for the approval of Boehringer's new anti-coagulant drug Pradaxa (dabigatran) for the country's Pharmaceutical Benefits Scheme
Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports